Edition:
United States

Novartis AG (NOVN.S)

NOVN.S on Virt-X Level 1

82.90CHF
4:03am EST
Change (% chg)

CHF-0.10 (-0.12%)
Prev Close
CHF83.00
Open
CHF82.95
Day's High
CHF83.15
Day's Low
CHF82.70
Volume
488,250
Avg. Vol
4,082,763
52-wk High
CHF85.40
52-wk Low
CHF69.50

Chart for

About

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company's segments include Innovative Medicines, Sandoz, Alcon and Corporate activities. Innovative Medicines... (more)

Overall

Beta: 1.06
Market Cap(Mil.): CHF216,957.50
Shares Outstanding(Mil.): 2,616.84
Dividend: 2.75
Yield (%): 3.31

Financials

  Industry Sector
P/E (TTM): -- 32.13 15.67
EPS (TTM): -- -- --
ROI: -- 15.10 34.62
ROE: -- 16.59 16.00

GSK's new pharma head on lookout for cancer deals to boost pipeline

LONDON GlaxoSmithKline will scout for deal opportunities in cancer medicine, as well as immunology, as the drugmaker seeks to rebuild its presence in oncology, its new head of pharmaceuticals told Reuters.

Dec 11 2017

'Unheard of' responses to bluebird CAR-T therapy seen in myeloma study

More than half of patients with advanced multiple myeloma who had run out of therapeutic options remained in complete remission after receiving bluebird bio Inc's experimental gene-modifying immunotherapy in a small, early stage study, according to updated data released on Sunday.

Dec 10 2017

'Unheard of' responses to bluebird CAR-T therapy seen in myeloma study

Dec 10 More than half of patients with advanced multiple myeloma who had run out of therapeutic options remained in complete remission after receiving bluebird bio Inc's experimental gene-modifying immunotherapy in a small, early stage study, according to updated data released on Sunday.

Dec 10 2017

Roche, Novartis' Italian heads risk trial for alleged market rigging: sources

ROME The local heads of Swiss drugmakers Roche and Novartis risk facing trial in Italy for alleged market manipulation, judicial sources said on Friday.

Dec 08 2017

Roche, Novartis' Italian heads risk trial for alleged market rigging- sources

ROME, Dec 8 The local heads of Swiss drugmakers Roche and Novartis risk facing trial in Italy for alleged market manipulation, judicial sources said on Friday.

Dec 08 2017

BRIEF-Novartis Division Sandoz Says New Phase I Data Showing Proposed Biosimilar Pegfilgrastim Matches Reference Medicine‍​

* DIVISION SANDOZ SAYS NEW PHASE I DATA SHOWING PROPOSED BIOSIMILAR PEGFILGRASTIM MATCHES REFERENCE MEDICINE‍​ Source text for Eikon: Further company coverage: (Reporting by John Miller)

Dec 08 2017

BRIEF-Advanced Accelerator Applications Announces Commencement Of Novartis Tender Offer

* ADVANCED ACCELERATOR APPLICATIONS ANNOUNCES COMMENCEMENT OF NOVARTIS TENDER OFFER

Dec 07 2017

BRIEF-Novartis Says Premenopausal Women Taking Kisqali Benefited For Longer Time Until Health-Related QOL Deterioration

* NOVARTIS KISQALI IS FIRST AND ONLY CDK4/6 INHIBITOR TO SHOW SUPERIOR MEDIAN PFS COMPARED TO ORAL ENDOCRINE THERAPY AS FIRST-LINE TREATMENT IN A PROSPECTIVE, RANDOMIZED PHASE III TRIAL DEDICATED TO PREMENOPAUSAL WOMEN WITH HR+/HER2- ADVANCED BREAST CANCER

Dec 06 2017

Australian watchdog takes GlaxoSmithKline, Novartis units to court

The Australian Competition and Consumer Commission (ACCC) on Wednesday said it is taking local units of GlaxoSmithKline and Swiss healthcare company Novartis to court over false or misleading representations in the marketing of pain relief products.

Dec 05 2017

UPDATE 1-Australian watchdog takes GlaxoSmithKline, Novartis units to court

Dec 6 The Australian Competition and Consumer Commission (ACCC) on Wednesday said it is taking local units of GlaxoSmithKline and Swiss healthcare company Novartis to court over false or misleading representations in the marketing of pain relief products.

Dec 05 2017

Earnings vs. Estimates